COGTCogent Biosciences, Inc.

Healthcare
$31.18+91% 1Y

The financials

Cogent Biosciences, Inc. by the numbers

The next results filing is expected around Nov 2, 2026, the same week as a year ago.

Cogent Biosciences, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$103M−$76Mn/a
Net income−$96M−$74Mn/a
Diluted EPS−$0.52−$0.53n/a
On our screens:Most shorted stocks

Biotechnology

Ranks #87 of 194 by RyuScore

Compare peers
CGON-1.4%
CG Oncology, Inc.
KOD+2.2%
Kodiak Sciences Inc.
ORKA-1.2%
Oruka Therapeutics, Inc.
MIRM-3.2%
Mirum Pharmaceuticals, Inc.
PTCT-3.8%
PTC Therapeutics, Inc.
SRRK-1.2%
Scholar Rock Holding Corporation